Trinity Biotech (TRIB) Reports Q4 Loss of $0.23/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Trinity Biotech Announces Q3 2022 Financial Results
December 15, 2022 9:05 AM ESTDUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Companys results for the quarter ended September 30, 2022.
Summary Highlights:
Total revenues for Q3 2022 were $19.5m. Excluding our Covid focused PCR Viral Transport Media (VTM) products, Q3 2022 revenues of $19.2m were marginally higher by 2% compared to Q3 2021 and were up 6% compared to Q2 2022.A strong YoY 30% increase in revenues attributable to both our Haemoglobins and Fitzgerald... More